消息面上，11月6日晚，兆科眼科宣布，公司已与印度尼西亚领先制药公司PT Ferron Par Pharmaceuticals("PT Ferron")，就公司核心产品之一、用于治疗老花眼的创新药物BRIMOCHOL PF，签 订了一份针对印度尼西亚市场的分销和供应协议。该药物授权引进自Tenpoint Therapeutics,Ltd.。根据协 议条款，兆科眼科授予PT Ferron在印度尼西亚进口、推广、分销、营销和销售该产品的独家权利。兆 科眼科将获得一笔预付款项，并可根据若干成就获得额外的里程碑付款。 此外，兆科眼科的合作伙伴、BRIMOCHOL PF的研发者Tenpoint Therapeutics于2025年6月公布，美国食 品药品管理局已经接受了该药物的新药上市申请，并将《处方药使用者付费法案》("PDUFA")日期定于 2026年1月28日。 兆科眼科-B(06622)涨超7%，截至发稿，涨7.64%，报3.38港元，成交额238.93万港元。 ...

智通财经11月6日讯（编辑 冯轶）智通财经为您带来今日港股重要公告 1）公司要闻 百济神州(06160.HK)：前9月总收入约38.45亿美元，同比增长43%；经调整净利润约6.93亿美元，同比扭亏为盈。其中，三季度收入达14.12亿美元，同比增 长41%；经调整净利润约3.04亿美元，同比增长489%。 公告称，主要得益于百悦泽®在美国和欧洲的销售额增长，目前美国仍是公司最大的市场。公司全年总收入指引为51亿美元至53亿美元，其中包 括收入强劲增长的预期，受益于百悦泽®在美国的领先地位以及在欧洲和全球其他重要市场的持续扩张。 东风集团股份(00489.HK)：前10个月累计汽车销量为150.1万辆，同比下降约1.6%。其中，新能源汽车销量为42.14万辆，同比增长约37.1%。 中国海外发展(00688.HK)：前10个月累计合约物业销售金额约1891.65亿元，同比下跌21.3%。 保利置业集团(00119.HK)：前10个月累计合约销售金额438亿元，同比减少10.43%。 金地商置(00535.HK)：前10个月累计合约销售金额约91.25亿元，同比减少43.93%。 融创中国(01918.HK)：前 ...

Group 1 - Company Zhaoke Ophthalmology-B (06622) has entered into a distribution and supply agreement with PT Ferron Par Pharmaceuticals for the commercialization of BRIMOCHOL PF in Indonesia [1] - The agreement grants PT Ferron exclusive rights to import, promote, distribute, market, and sell BRIMOCHOL PF in Indonesia, with the company receiving an upfront payment and potential milestone payments based on specific achievements [1] - BRIMOCHOL PF is an experimental preservative-free eye drop designed to correct near vision loss due to aging, with a new drug application accepted by the FDA, and a review deadline set for January 28, 2026 [1][2] Group 2 - PT Ferron Par Pharmaceuticals, a member of the Dexa Group, has been operating since 2001 and is recognized as one of the top 15 largest pharmaceutical companies in Indonesia [3] - The company has received recognition from regulatory bodies such as the UK's Medicines and Healthcare products Regulatory Agency and Portugal's National Authority of Medicines and Health Products, enhancing its credibility [3] - PT Ferron is known for its diverse product portfolio, advanced production capabilities, and strong strategic partnerships, which contribute to its growing market influence and operational excellence [3]

BRIMOCHOL PF为一款不含防腐剂、每日一次实验性滴眼液，用于矫正因老化丧失近距离视力。 BRIO-II为一项针对BRIMOCHOL PF(卡巴胆硷╱酒石酸溴莫尼丁固定剂量复方)局部滴眼液、卡巴胆硷 单一疗法局部滴眼液及载体局部滴眼液的三臂、多中心、随机、双盲的安全性及疗效研究，受试者为正 视晶状体或人工晶状体老花眼患者(NCT05135286)。该研究于美国47个试验中心共入组629名受试者。 PT Ferron Par Pharmaceuticals于2001年开始营运，为Dexa集团旗下成员公司，是一间快速发展的制药公 司。PT Ferron已成为印度尼西亚首15间最大型制药公司之一(根据IQVIA的2025年首季IPA及IHPA合并 MAT资料)。其设施已获英国药物及健康产品监管局(Medicines and Healthcare products Regulatory Agency(MHRA))及葡萄牙国家药品与健康产品管理局(National Authority of Medicines and Health Products(Infarmed))认可。凭借多元化的产品组合、先进的生产能力及 ...

Core Viewpoint - The company reported a significant decline in revenue and an increase in net loss for the six months ending June 30, 2025, primarily due to changes in sales strategy and increased R&D expenses [1] Financial Performance - Revenue for the period was 15.803 million, representing a year-on-year decrease of 68.25% [1] - The net loss amounted to 117 million, which is an increase of 53.85% compared to the previous period [1] Reasons for Financial Changes - The increase in net loss is attributed to the absence of one-time licensing income recognized in the previous period under a product licensing agreement [1] - Increased R&D expenses were driven by the initiation of Phase I and II clinical trials for BRIMOCHOL PF and CARBACHOL PF, as well as a new Phase III clinical trial for cyclosporine eye gel [1] - The decrease in revenue is linked to the company's shift in sales strategy, focusing on expanding the distribution network for ophthalmic drugs and restructuring the sales team to concentrate on key sales regions [1]